Badreddin Edris has sold stock and made no open-market buys since Jan 2021

Badreddin Edris, Ph.D., is a biotechnology executive, investor, and director, currently serving on the board of directors of Edgewise Therapeutics, Inc., where he is also a co‑founder and former strategic advisor and operator.( As a director at Edgewise Therapeutics (NASDAQ: EWTX), he has been involved in the company’s governance and has engaged in multiple insider equity transactions, including option exercises, stock sales under a Rule 10b5‑1 plan, and director equity awards.( In parallel, Dr. Edris is President and Chief Operating Officer of Beeline Medicines, where he leads efforts to build and scale a biopharmaceutical company from drug discovery through commercialization, and he serves as a Venture Partner at The Column Group.(

Earlier in his career, Dr. Edris was Chief Operating Officer of SpringWorks Therapeutics (NASDAQ: SWTX), a clinical‑stage biopharmaceutical company focused on rare diseases and cancer, where he led strategic planning, business development, capital formation, investor relations, competitive intelligence, and helped drive regulatory approvals, product launches, and the company’s eventual sale to Merck KGaA, Darmstadt, Germany.( Before that, he was an investment and operating professional on the private equity team at OrbiMed, where he focused on venture investments and company creation, including co‑founding Silverback Therapeutics and Edgewise Therapeutics, and previously worked as a management consultant at Bain & Company, advising global pharmaceutical and biotechnology companies.( Dr. Edris holds a Ph.D. in genetics from Stanford University School of Medicine, where he was an NSF research fellow.(

Written by Perplexity from public sources.